We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: The Procter & Gamble Co., Chevron Corp., Novo Nordisk A/S, FedEx Corp. and Palo Alto Networks, Inc
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 28, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Procter & Gamble Co. (PG - Free Report) , Chevron Corp. (CVX - Free Report) , Novo Nordisk A/S (NVO - Free Report) ,FedEx Corp. (FDX - Free Report) and Palo Alto Networks, Inc. (PANW - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Procter & Gamble, Chevron and Novo Nordisk
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Co. (PG - Free Report) , Chevron Corp. (CVX - Free Report) , and Novo Nordisk A/S (NVO - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Procter & Gamble have outperformed the Zacks Soap and Cleaning Materials industry over the past year (+22.9% vs. +11.3%). While the company has reported earnings surprises for the more than three years straight, revenues beat estimates for the seventh time in a row for second-quarter fiscal 2022.
The Zacks analyst believes that results were driven by improved productivity amid cost headwinds, along with the rising demand for cleaning products due to the resurgence of COVID-19 cases. Management lifted its fiscal 2022 view.
It witnessed SG&A expense leverage, owing to savings from overhead and marketing expenses, and cost leverage gains due to higher sales and real estate. However, unfavorable mix, commodity cost inflation, increase in freight costs, product and packaging investments and other impacts hurt margins. It expects higher commodity and freight costs to persist in fiscal 2022.
Shares of Chevron have outperformed the Zacks Soap and Cleaning Materials industry over the past year (+22.9% vs. +11.3%). The Zacks analyst believes that based on a slew of tailwinds, the company seems poised for further capital appreciation. The supermajor is considered one of the best placed integrated oil firms to achieve sustainable production growth. America’s No. 2 energy company’s project pipeline is among the best in the industry, thanks to its premier position in the lucrative Permian Basin.
Chevron’s Noble Energy takeover expanded its footprint in the region and the DJ Basin along with the addition of cash generating offshore assets in Israel. In shareholder friendly moves, the integrated major recently hiked its dividend twice and revived the stock repurchase program. Consequently, Chevron is viewed as a preferred energy major to own now.
Shares of Novo Nordisk have underperformed the Zacks Large Cap Pharmaceuticals industry in the year to date period (-11.7% vs. -7.2%). The Zacks analyst believes that the company continues to face pricing pressure from other players in the diabetes market which is a concern. Moreover, lower realized prices in the United States, loss of exclusivity for products and stiff competition are affecting sales.
Sales are also being negatively impacted by the COVID-19 pandemic. Also, the supply challenges for Wegovy has hurt the stock. The patent expiry on some of the products in Novo Nordisk’s portfolio is concerning too.
However, its marketed drug, Ozempic, is off to a solid start. The launch of Rybelsus also looks impressive. Ozempic, Rybelsus, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of existing drugs is likely to further boost sales.
Other noteworthy reports we are featuring today include FedEx Corp. (FDX - Free Report) and Palo Alto Networks, Inc. (PANW - Free Report) .
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: The Procter & Gamble Co., Chevron Corp., Novo Nordisk A/S, FedEx Corp. and Palo Alto Networks, Inc
For Immediate Release
Chicago, IL – February 28, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Procter & Gamble Co. (PG - Free Report) , Chevron Corp. (CVX - Free Report) , Novo Nordisk A/S (NVO - Free Report) ,FedEx Corp. (FDX - Free Report) and Palo Alto Networks, Inc. (PANW - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Procter & Gamble, Chevron and Novo Nordisk
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Co. (PG - Free Report) , Chevron Corp. (CVX - Free Report) , and Novo Nordisk A/S (NVO - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Procter & Gamble have outperformed the Zacks Soap and Cleaning Materials industry over the past year (+22.9% vs. +11.3%). While the company has reported earnings surprises for the more than three years straight, revenues beat estimates for the seventh time in a row for second-quarter fiscal 2022.
The Zacks analyst believes that results were driven by improved productivity amid cost headwinds, along with the rising demand for cleaning products due to the resurgence of COVID-19 cases. Management lifted its fiscal 2022 view.
It witnessed SG&A expense leverage, owing to savings from overhead and marketing expenses, and cost leverage gains due to higher sales and real estate. However, unfavorable mix, commodity cost inflation, increase in freight costs, product and packaging investments and other impacts hurt margins. It expects higher commodity and freight costs to persist in fiscal 2022.
(You can read the full research report on Procter & Gamble here >>>)
Shares of Chevron have outperformed the Zacks Soap and Cleaning Materials industry over the past year (+22.9% vs. +11.3%). The Zacks analyst believes that based on a slew of tailwinds, the company seems poised for further capital appreciation. The supermajor is considered one of the best placed integrated oil firms to achieve sustainable production growth. America’s No. 2 energy company’s project pipeline is among the best in the industry, thanks to its premier position in the lucrative Permian Basin.
Chevron’s Noble Energy takeover expanded its footprint in the region and the DJ Basin along with the addition of cash generating offshore assets in Israel. In shareholder friendly moves, the integrated major recently hiked its dividend twice and revived the stock repurchase program. Consequently, Chevron is viewed as a preferred energy major to own now.
(You can read the full research report on Chevron here >>>)
Shares of Novo Nordisk have underperformed the Zacks Large Cap Pharmaceuticals industry in the year to date period (-11.7% vs. -7.2%). The Zacks analyst believes that the company continues to face pricing pressure from other players in the diabetes market which is a concern. Moreover, lower realized prices in the United States, loss of exclusivity for products and stiff competition are affecting sales.
Sales are also being negatively impacted by the COVID-19 pandemic. Also, the supply challenges for Wegovy has hurt the stock. The patent expiry on some of the products in Novo Nordisk’s portfolio is concerning too.
However, its marketed drug, Ozempic, is off to a solid start. The launch of Rybelsus also looks impressive. Ozempic, Rybelsus, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of existing drugs is likely to further boost sales.
(You can read the full research report on Novo Nordisk here >>>)
Other noteworthy reports we are featuring today include FedEx Corp. (FDX - Free Report) and Palo Alto Networks, Inc. (PANW - Free Report) .
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
See Stocks Now >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.